Fig. 1: Relapse and repeated CD19 CAR T cell therapy in a patient with Jo-1+ IIM. | Nature Medicine

Fig. 1: Relapse and repeated CD19 CAR T cell therapy in a patient with Jo-1+ IIM.

From: BCMA CAR T cells in a patient with relapsing idiopathic inflammatory myositis after initial and repeat therapy with CD19 CAR T cells

Fig. 1

a, Serum CK levels after CD19 CAR T cell therapy and at relapse. The horizontal dotted line indicates the upper limit of normal range (<170 U per l). b, Muscle strength as indicated by MMT8 score. c, CD19 CAR+CD3+ T cell counts in blood. d, CD19+ B cell counts in blood. e–h, Counts of leukocytes (e); neutrophils (f); CD4+ T cells (g) and CD8+ T cells (h) in blood after lymphodepletion (in cells per µl). i, ELISA quantification of the humoral response to CAR (FMC63). j, Quantification of the anti-CAR T cell response in control donors and the index patient. k, Sequence of events demonstrating the onset of the anti-CAR T cell response and humoral response. Unstim, no T cell stimulation; +, stimulated T cells.

Back to article page